ASSESS THE EFFICACY & SAFETY OF CEP-1347 IN PTS W/EARLY PARKINSON'S DISEASE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine if treatment with CEP-1347 delays the time to onset of disability sufficient to require dopaminergic therapy in individuals with Parkinson's disease. Secondary objectives are to assess the effect of CEP-1347 on dopaminergic transporter density using a brain imaging technique, to assess the safety and tolerability of this drug in patients with Parkinson's disease, and to identify the appropriate dose of CEP-1347 for further clinical development.

Clin-STAR Database